PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas

被引:440
作者
Lee, JW [1 ]
Soung, YH [1 ]
Kim, SY [1 ]
Lee, HW [1 ]
Park, WS [1 ]
Nam, SW [1 ]
Kim, SH [1 ]
Lee, JY [1 ]
Yoo, NJ [1 ]
Lee, SH [1 ]
机构
[1] Catholic Univ Korea, Coll Med, Dept Pathol, Seoul 137701, South Korea
关键词
PIK3CA; mutation; cancer; oncogene;
D O I
10.1038/sj.onc.1208304
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A recent report revealed that phosphoinositide-3-kinase, catalytic, alpha (PIK3CA) gene is somatically mutated in several types of human cancer, suggesting the mutated PIK3CA gene as an oncogene in human cancers. However, because the previous report focused the mutational search primarily on colon cancers, the data on PIK3CA mutations in other types of human cancers have been largely unknown. Here, we performed mutational analysis of the PIK3CA gene by polymerase chain reaction-single-strand conformation polymorphism assay in 668 cases of common human cancers, including hepatocellular carcinomas, acute leukemias, gastric carcinomas, breast carcinomas, and non-small-cell lung cancers. We detected PIK3CA somatic mutations in 26 of 73 hepatocellular carcinomas (35.6%), 25 of 93 breast carcinomas (26.9%), 12 of 185 gastric carcinomas (6.5%), one of 88 acute leukemias (1.1%), and three of 229 non-small-cell lung cancers (1.3%). Some of the PIK3CA mutations were detected in the early lesions of breast cancer carcinoma, hepatocellular carcinoma, and gastric carcinomas, suggesting that PIK3CA mutation may occur independent of stage of the tumors. The high incidence and wide distribution of PIK3CA gene mutation in the common human cancers suggest that alterations of lipid kinase pathway by PIK3CA mutations contribute to the development of human cancers.
引用
收藏
页码:1477 / 1480
页数:4
相关论文
共 24 条
  • [1] HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer
    Arteaga, CL
    Moulder, SL
    Yakes, FM
    [J]. SEMINARS IN ONCOLOGY, 2002, 29 (03) : 4 - 10
  • [2] MOLECULAR ALTERATIONS OF THE AKT2 ONCOGENE IN OVARIAN AND BREAST CARCINOMAS
    BELLACOSA, A
    DEFEO, D
    GODWIN, AK
    BELL, DW
    CHENG, JQ
    ALTOMARE, DA
    WAN, MH
    DUBEAU, L
    SCAMBIA, G
    MASCIULLO, V
    FERRANDINA, G
    PANICI, PB
    MANCUSO, S
    NERI, G
    TESTA, JR
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1995, 64 (04) : 280 - 285
  • [3] A specific function for phosphatidylinositol 3-kinase α (p85α-p110α) in cell survival and for phosphatidylinositol 3-kinase β (p85α-p110β) in de novo DNA synthesis of human colon carcinoma cells
    Bénistant, C
    Chapuis, H
    Roche, S
    [J]. ONCOGENE, 2000, 19 (44) : 5083 - 5090
  • [4] EARLY GASTRIC-CANCER
    BOGOMOLETZ, WV
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1984, 8 (05) : 381 - 391
  • [5] The phosphoinositide 3-kinase pathway
    Cantley, LC
    [J]. SCIENCE, 2002, 296 (5573) : 1655 - 1657
  • [6] New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase AKT pathway
    Cantley, LC
    Neel, BG
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (08) : 4240 - 4245
  • [7] Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the philadelphia chromosome.
    Druker, BJ
    Sawyers, CL
    Kantarjian, H
    Resta, DJ
    Reese, SF
    Ford, JM
    Capdeville, R
    Talpaz, M
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) : 1038 - 1042
  • [8] EDMONDSON HA, 1954, CANCER-AM CANCER SOC, V7, P462, DOI 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO
  • [9] 2-E
  • [10] Inactivating mutations of caspase-8 gene in colorectal carcinomas
    Kim, HS
    Lee, JW
    Soung, YH
    Park, WS
    Kim, SY
    Lee, JH
    Park, JY
    Cho, YG
    Kim, CJ
    Jeong, SW
    Nam, SW
    Kim, SH
    Lee, JY
    Yoo, NJ
    Lee, SH
    [J]. GASTROENTEROLOGY, 2003, 125 (03) : 708 - 715